StockData
Evolus, Inc. logo

Evolus, Inc. (EOLS) stock

EOLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$7.07+0.38 (+5.68%)

Close on Nov 18, 2026Market cap $466.98MP/E –Yield –

Evolus net income

Net income is the profit left for shareholders after every expense, interest and tax.

Evolus's net income for the twelve months ending Jun 30, 2026 was -$34.33M. For fiscal 2025 it was -$51.64M. The highest annual figure on record is -$4.48M in fiscal 2017.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$51.64M–
FY2024Dec 31, 2024-$50.42M–
FY2023Dec 31, 2023-$61.69M–
FY2022Dec 31, 2022-$74.41M–
FY2021Dec 31, 2021-$46.81M–
FY2020Dec 31, 2020-$163.01M–
FY2019Dec 31, 2019-$90.03M–
FY2018Dec 31, 2018-$46.87M–
FY2017Dec 31, 2017-$4.48M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$8.05M–
Q1 FY2026Mar 31, 2026-$10.67M–
Q4 FY2025Dec 31, 2025$130.00K–
Q3 FY2025Sep 30, 2025-$15.74M–
Q2 FY2025Jun 30, 2025-$17.14M–
Q1 FY2025Mar 31, 2025-$18.89M–
Q4 FY2024Dec 31, 2024-$6.79M–
Q3 FY2024Sep 30, 2024-$19.17M–
Q2 FY2024Jun 30, 2024-$11.35M–
Q1 FY2024Mar 31, 2024-$13.11M–
Q4 FY2023Dec 31, 2023-$11.83M–
Q3 FY2023Sep 30, 2023-$16.92M–
Q2 FY2023Jun 30, 2023-$18.14M–
Q1 FY2023Mar 31, 2023-$14.79M–
Q4 FY2022Dec 31, 2022-$13.16M–
Q3 FY2022Sep 30, 2022-$20.28M–
Q2 FY2022Jun 30, 2022-$23.47M–
Q1 FY2022Mar 31, 2022-$17.50M-373.4%
Q4 FY2021Dec 31, 2021-$18.18M–
Q3 FY2021Sep 30, 2021-$19.43M–
Q2 FY2021Jun 30, 2021-$15.60M–
Q1 FY2021Mar 31, 2021$6.40M–
Q4 FY2020Dec 31, 2020-$110.69M–
Q3 FY2020Sep 30, 2020-$11.46M–
Q2 FY2020Jun 30, 2020-$21.13M–
Q1 FY2020Mar 31, 2020-$19.74M–
Q4 FY2019Dec 31, 2019-$14.51M–
Q3 FY2019Sep 30, 2019-$26.98M–
Q2 FY2019Jun 30, 2019-$37.57M–
Q1 FY2019Mar 31, 2019-$10.98M–
Q4 FY2018Dec 31, 2018-$12.44M-379.7%
Q3 FY2018Sep 30, 2018-$11.83M–
Q2 FY2018Jun 30, 2018-$16.43M–
Q1 FY2018Mar 31, 2018-$6.16M–
Q4 FY2017Dec 31, 2017$4.45M–
Q3 FY2017Sep 30, 2017-$2.63M–
Q2 FY2017Jun 30, 2017-$2.30M–
Q1 FY2017Mar 31, 2017-$4.00M–

More Evolus figures

See a number that looks wrong?